Genuine invitro diagnostics applicable to a range of cancers and in use for bladder cancer are not an inconsiderable upside. GC is not only horse in the SDX stable, there is a quality team here. I am here for the MT-LT, and while disappointed with the IPO subscription and post IPO price am looking at the upside making me $ by year end. Thinking all IPOs will make $ like AC8 or AL8 puts me in the wrong game. I am way ahead in the IPO stakes for 2017. Win a few, lose a few but come out on top in the end is my philosophy.
